Patented Compounds for Rheumatoid Arthritis: Advancing to New Standards in Restoration

The Significance of Patents in Rheumatoid Arthritis Restoration

EHL BIO's patent for rheumatoid arthritis compounds validates its cutting-edge innovation. The compounds are designed to address the root cause of the disease: immune system imbalance. This patent covers techniques using compounds that help normalize immune function, representing a major leap in improving quality of life.

Having a patent reinforces confidence in the research and development process of the institute, which focuses on finding restoration solutions for complex diseases with goals for recovery and quality of life. With over 85 researchers collaborating with partner hospitals across Korea and Thailand, EHL BIO ensures these innovations are applied to sustainably improve patients' quality of life.

Mechanism of Action: Immunotherapy Balancing

Rheumatoid arthritis is primarily caused by an imbalance between Th1 and Th2 T cells, leading to chronic inflammation that destroys joints and surrounding tissues. The stem cells and compounds developed by EHL BIO possess immune modulation properties that restore normal immune function, whether by boosting weakened immunity or suppressing excessive activity as per EHL team evaluation.

Furthermore, these compounds are developed alongside adipose-derived stem cell isolation and culture technology. This autologous approach reduces the risk of immune rejection, ensuring safety. The cells can then navigate to damaged areas through the 'Homing Effect' to perform targeted restoration.

This compound patent is a testament to EHL BIO's commitment to overcoming immune disease limitations and restoring quality of life to patients.

RASTEM Inj.: From Research to Clinical Application

Under EHL BIO’s research institute, RASTEM Inj. is a stem cell therapeutic developed specifically for rheumatoid arthritis. It is currently in the clinical trial preparation stage to test efficacy and safety. This product is the result of integrating patented technology with GMP (Good Manufacturing Practices) production standards, capable of producing up to 6,000 lots per year.

The development of RASTEM Inj. focuses on restoring cartilage tissue and reducing inflammation without the need for major surgery. This represents a new choice in the era of Regenerative Medicine, helping patients return to their daily lives through the cultivation and selection of high-quality cells with excellent survival rates.

Safety and Quality Control Standards

EHL BIO prioritizes safety above all, with production facilities certified at Class 100 and being the first in Korea to be authorized as a Human Cell Management Business under modern regenerative medicine laws. The entire process—from collection and isolation to cryopreservation at -196°C—is strictly controlled to maintain the optimal potency of the compounds and cell therapies.

Receiving honors like the 'Jang Young-shil Award' and the 'Minister of Health and Welfare Award' confirms our success and relentless research standards. Patients can be assured that patented innovations are monitored and quality-controlled according to EHL team evaluation, with the ultimate goal of achieving sustainable health.